background: Pre-implantation genetic diagnosis (PGD) is an assisted reproductive technology procedure which provides parents with the option of conducting genetic analyses to determine if a mutation is present in an embryo. Though studies have discussed perceptions of PGD from a general population, couples or high-risk women, no studies to date have specifically examined PGD usage among men. This study sought to explore perceptions and attitudes towards PGD among males who either carry a BRCA mutation or have a partner or first degree relative with a BRCA mutation. methods: A cross-sectional survey was conducted among 228 men visiting the Facing Our Risk of Cancer Empowered or Craigslist website. Eligibility criteria included men who self-reported they had been tested for a BRCA mutation or had a partner or first degree relative tested for a BRCA mutation. A 41-item survey assessed socio-demographic, clinical characteristics, PGD knowledge and attitudinal factors and consideration of the use of PGD. Differences in proportions of subgroups were tested using the Monte Carlo exact test for categorical data. A multiple logistic regression model was then built through a backward elimination procedure.
Introduction
Hereditary breast and ovarian cancer syndrome (HBOC) is the inherited tendency to develop breast, ovarian and other cancers and believed to be transmitted by mutations in the BRCA1 and BRCA2 (BRCA) genes. Risk of developing cancer is greatest in female BRCA carriers with a lifetime risk of developing breast cancer estimated at 60 -85% and an estimated 15 -40% lifetime risk of developing ovarian cancer (Struewing et al., 1997; Ford et al., 1998) . Men are also at an increased risk of developing breast cancer. Male BRCA2 carriers have a 6.9% cumulative lifetime risk (Thompson and Easton, 2001; Mohamad and Apffelstaedt, 2008; Daly, 2009 ) and male BRCA1 carriers have a 5.8% cumulative lifetime risk (Brose et al., 2002; Ottini et al., 2003) of developing breast cancer. Female and male BRCA carriers also have an increased risk for developing other cancers (The Breast Cancer Linkage Consortium, 1999; Friedenson, 2005; Mohamad and Apffelstaedt, 2008) . Carriers have a 50% chance of transmitting the mutation to an offspring (Mohamad and Apffelstaedt, 2008) . Similar to women, studies have shown that men worry about transmitting the BRCA gene to future offspring (Strømsvik et al., 2009) .
Although sparse, the existing literature on males with known BRCA genetic mutations suggest men may feel stigmatized (Strømsvik et al., 2009 ); a sense of psychological distress if they were the first sibling in their family tested (Smith et al., 1999) and experience grief and fear related to concerns about developing cancer (Smith et al., 1999; Strømsvik et al., 2010) . Male BRCA carriers are at an increased risk of developing breast cancer which is perceived as a female disease, often leading to further anxiety and stigmatization (Strømsvik et al., 2010) . Men may also be concerned about their children's risk of cancer and have increased anxiety which has been shown to be dependent on the number of female children they have (d'AgincourtCanning, 2001) .
Women usually take the lead in communicating genetic information within and across their families, because male carriers often find it difficult to share test result with their children or siblings (Strømsvik et al., 2010) . Even among men who are tested and found to be non-carriers, feelings of guilt are expressed (Hallowell et al., 2006) along with difficulties in discussing tests results with their mutation-positive relatives (Goelen et al., 1999) . Hollowell et al. reported that male BRCA1/2 carriers have fatalistic attitudes and associate their carrier status with fate or predestination (Hallowell et al., 2006) . As with other predictive testing, genetic testing for BRCA mutations among males may have a negative impact on familial relationships and may further exasperate feelings of guilt, blame and resentment among family members (Hallowell et al., 2006) . Spouses or partners of male carriers may influence the decision-making about BRCA testing in order to decide whether or not to have children. If males are positive for BRCA mutations, couples may choose to utilize further assisted reproductive technology (ART), such as pre-implantation genetic diagnosis (PGD), to reduce risk to their offspring.
PGD is one of the ART procedures providing parents with the option of conducting genetic analyses to determine if a mutation is present in an embryo (Ogilvie et al., 2001; Baruch et al., 2008; Klitzman et al., 2008; Staton et al., 2008; Fortuny et al., 2009) . PGD is used in combination with in vitro fertilization (IVF), intracytoplasmic sperm injection and embryo biopsy (Fortuny et al., 2009 ). As of 2006, there have been 15 000 IVF cycles with PGD performed in the USA (Klitzman et al., 2008) .
Though studies have discussed PGD in regard to the general population, (Smith et al., 1999; Meister et al., 2005) couples (Lammens et al., 2009) , and high-risk women (Menon et al., 2007; Quinn et al., 2008; Vadaparampil et al., 2009) , and a few studies regarding prenatal testing, such as amniocentesis (Rappaport, 2008) , have specifically examined the roles and thoughts of males, no studies to date have specifically examined PGD usage among men (Browner and Preloran, 1999; Fernández et al., 2004; Borkenhagen et al., 2007) .
The use of PGD for adult onset hereditary cancers, such as HBOC is controversial and is currently the subject of debate in some countries where use for HBOC is not permitted. The focus of the controversy is centred on the fact that a mutation in the BRCA gene increases susceptibility for cancer risk but does not equate to certainty for developing cancer (Lammens et al., 2009 ). Other conditions for which a genetic mutation is related to certainty of development of the disease, such as Huntington's have been deemed more acceptable to the general public (Robertson, 2003) .
The purpose of this study was to explore perceptions and attitudes towards PGD among men who self-reported they were tested for a BRCA mutation or have a partner or immediate relative who was tested for a BRCA mutation, and to determine factors associated with consideration of the use of PGD. Respondents who completed the survey had the option of entering a raffle to win one of four $25.00 gift cards. The survey was limited to men who self-reported having had BRCA testing or a family member or partner who received testing, and were positive for the mutation.
Materials and Methods

Recruitment process
Instrument
The original survey was developed for high-risk women (HBOC) and administered to 125 women attending a FORCE conference (Quinn et al., 2008) and 962 females via the FORCE website (Vadaparampil et al., 2009) . The 41-item survey took 10 min to complete. The domains of the survey are shown in Supplementary data, Fig. S1 (copies of the original survey are available from the authors). Respondents were required to respond to a question indicating how they had heard about the survey; the choices included: (i) FORCE email or website (ii) Craigslist and (iii) other.
The survey assessed socio-demographic factors, as well as clinical, awareness and attitudinal factors, and asked whether the males concerned about HBOC would 'ever consider the use of PGD'.
Socio-demographic characteristics
The following self-reported socio-demographic characteristics were assessed: race/ethnicity (Daly, 2009) ; marital status; education; age; religion; currently have children and wish to have more children.
Clinical characteristics
The following self-reported clinical characteristics were assessed: personal history of breast cancer; personal history of prostate cancer; having seen a genetic counsellor; genetic testing for BRCA; test results; fear of passing BRCA mutation; and first degree relative diagnosed with breast cancer/ovarian cancer, family member who is BRCA positive, or partner or spouse diagnosed with breast cancer/ ovarian cancer; whether their spouse/partner have ever used IVF.
Awareness of PGD
Participants were asked whether they had heard of PGD testing prior to the current survey.
Attitudes related to PGD
Previous literature suggests a lack of PGD awareness among individuals at increased risk for HBOC (Menon et al., 2007; Quinn et al., 2008; Staton et al., 2008) . Therefore, participants were provided with a brief definition of PGD: 'Pre-implantation Genetic Diagnosis (PGD) is a genetic test performed on embryos produced through in vitro fertilization and used to determine if they are with or without a gene mutation. Test results are used to inform prospective parents about the status of the embryos before transfer to a woman's uterus' (Offit et al., 2006) . This definition was followed by a series of attitudinal items adapted from a survey conducted by the Genetics and Public Policy Center on public's attitudes towards ART (Hudson, 2006; Queller, 2008) .
Consideration of the use of PGD
Respondents were asked whether they and their spouse (significant other) would 'ever consider the use of PGD'.
Statistical analysis
All analyses were performed using the statistical software package SAS (SAS 9.1: SAS Institute Inc.). To test differences in proportions of the two subgroups (e.g. FORCE and Craigslist), the Monte Carlo exact test for categorical data was used. Any variable with a P , 0.10 (twotailed) was regarded as statistically significant. The proportion of individuals who selected the option yes was compared with those who responded no/not sure to 'ever consider the use of PGD' using the Monte Carlo exact test at significance level ,0.10. A multiple logistic regression model was then built through a backward elimination procedure. The procedure starts with a model in which all variables are included, then proceeds to a final model in which only those variables significant at the 0.10 level are included.
Results
The final sample included 228 men. Of the 228 men, 25% had personally seen a genetic counsellor and 33% had genetic testing for a BRCA mutation. Of those participating in genetic testing, 33% were positive; 29% were negative; 8% had variants of uncertain significance; 15% were uninformative/inconclusive/indeterminate; 2% preferred not to answer and 4% did not know their results. The remainder of the participants reported having either a spouse or a partner who was BRCA positive (16%) or a first degree female relative with a BRCA mutation (21%). The remaining 30% of respondents selected 'do not know or prefer not to answer' regarding their BRCA status. The majority of respondents were white males (68.9%), ≤41 years of age (56.1%), and had college education (85.5%). In addition, approximately half of the men were married (46.9%), had children (54.4%) and were fearful of passing a BRCA mutation to their children (52.2%). The most common religious affiliations selected were Catholic (30.7%) and Christian/Protestant (30.3%). The vast majority had no personal history of breast (96.9%) or prostate cancer (96.1%). However, 33.9% of the respondents had a first degree relative with breast or ovarian cancer. Prior to the survey, the majority of the men had not heard of PGD (78.5%) and their spouse or partner had not used IVF (64%).
Bivariate analyses
A bivariate analysis was conducted comparing the two groups (FORCE versus Craigslist). Factors showing significance were: race/ ethnicity (P , 0.05); martial status (P , 0.01); age (P , 0.01); religion (P , 0.01); having children (P , 0.01); personal history of breast cancer (P , 0.02); family member BRCA positive (P , 0.01); spouse/partner BRCA positive (P , 0.01); and how PGD is considered (P , 0.01). However, there were no statistically significant differences between the two groups for PGD concerns, benefits of PGD and how PGD is considered.
Among the 228 respondents, 78 (34.2%) selected the option that they would 'ever consider the use of PGD', and 150 (65.7%) would not consider the use of PGD or selected 'not sure'. 'Ever consider the use of PGD' by demographic and clinical variables is presented in Table I . Demographic variables, clinical characteristics and having heard of PGD prior to the survey were not significantly associated with whether participants would 'ever consider the use of PGD'. 'Ever consider the use of PGD' by awareness and attitudinal factors is presented in Table II . Those who would 'ever consider the use of PGD' were most concerned about affordability (39.7%) and felt the greatest benefit of PGD was parents improving the chances their baby will be free of genetic mutations (55.1%). When asked how they consider PGD, the majority of males who would consider PGD or would not consider/not sure, said that it was mainly a 'health and safety issue' (69.2 and 42%, respectively). Attitudinal factors significantly associated with 'ever consider the use of PGD' were: concerns (P , 0.01); benefits (P , 0.01); and how PGD is considered (P , 0.01).
Multivariable analyses
Two factors were independently associated with 'ever consider the use of PGD' in the multivariable analysis (Table III) . Regarding PGD benefits, those respondents who selected the 'other' option (OR ¼ 0.14; 95% 0.03-0.56) were less likely to 'ever consider the use of PGD' compared with respondents who felt 'cost of health care will be less'. Of the respondents who selected the 'other' option 'improving parents' chances of having an offspring free of genetic mutations' was the consensus among the respondents who wrote comments. Respondents who thought of PGD in terms of 'health and safety' were almost three times more likely (OR ¼ 2.82; 95% 1.19 -6.71) to 'ever consider the use of PGD' compared with respondents who thought of PGD in terms of both 'health and safety' and 'religion and morality'.
Discussion
There have been several studies investigating attitudes towards PGD with couples or female BRCA carriers (Quinn et al., 2008; Fortuny et al., 2009; Lammens et al., 2009; Vadaparampil et al., 2009 ), but high-risk men's views on PGD have not been well studied.
In the present study, 80% of men reported being unfamiliar with PGD. Women tend to be responsible for maintaining the health of spouses and children (d'Agincourt-Canning, 2001; Hallowell et al., 2006) which may explain why the majority of men in our study and other studies about prenatal diagnoses might be unaware of PGD. However, in companion studies with women, low awareness of Continued PGD was similar. Of 962 high-risk women, 80% were unfamiliar with PGD (Vadaparampil et al., 2009) , and 78% of women at a national conference on HBOC had not heard of PGD prior to the survey (Quinn et al., 2008) . Meister et al. assessed PGD knowledge by asking participants in Germany to estimate whether they had heard, read or watched something about PGD (Meister et al., 2005) . Their findings indicated 60% of the sample was unaware of PGD and 10% were unsure; 44% of the total sample included men. Meister's study did not assess BRCA carrier or risk status among the participants. Approximately one-third of the males in the study (34%) indicated they would 'ever consider the use of PGD' and 65.7% would not or were 'not sure'. Although, Lammens et al. reported 48% of participants would consider the use of PGD, participants were both males and females (Lammens et al., 2009 Monte Carlo exact test P-value (15 out of 243 total subjects have missing value for the question 'Do you or your spouse ever consider using PGD'). *P , 0.10.
more willing to consider the use of PGD than women or that men may be more likely to respond they are uncertain about consideration of PGD use. However, men in the present study had equal rates of consideration compared with women as evidenced from two previous studies with only female participants. The Vadaparampil et al. (2009) , study showed 33% would consider the use PGD and a study by Quinn et al. (2008) found that 33% would consider the use of PGD. In a study by Menon et al. (2007) , 75% of a sample of BRCA mutation carriers (n ¼ 52) considered it acceptable to offer PGD, but only 14% would consider personal use. Improving parents' chances of having an offspring free of genetic mutations was one of the factors associated with 'ever consider the use of PGD' in the current study. Similarly, the study by Vadaparampil et al. (2009) of 962 women also described health of offspring as the greatest benefit of PGD. However, avoiding pregnancy termination was the most important advantage of PGD in the study conducted by Lammens et al. (2009) . Among Australian parents, 26% expressed concerns about their child's future health and vulnerability, after conceiving through IVF (Robertson, 2004) . Besides the concerns to their future offspring, men may worry about spouses or significant others who are BRCA carriers, as they may be at increased personal cancer risk from the hormone treatment used to stimulate ovulation via IVF (Lerner-Geva et al., 2006) .
In the current study, 'ever consider the use of PGD' among males could oscillate if they were in a relationship and were seriously considering use of the procedure. Participants were unfamiliar with the term PGD and therefore likely unfamiliar with the financial costs associated. For example, in the USA, individuals may spend anywhere from $10 000-$15 000 per cycle for IVF and embryo testing may cost an additional $2500-$6000 (Simpson et al., 2005) . Typically, couples often require more than one cycle of IVF for a successful outcome of pregnancy and live birth (Klitzman et al., 2008) .
Many countries regulate, govern, recommend and limit the criteria for various ART procedures, particularly PGD, although the USA does not (Basille et al., 2009) . In a recent report, approximately one dozen embryo transfers utilizing PGD among BRCA mutation carriers have been performed in several IVF clinics in the USA (Offit et al., 2006) . The USA does not collect systematic data on the health of children born following PGD, but the Centers for Disease Control and Prevention does require IVF clinics to report treatment outcomes, such as number of initiated IVF cycles and percentage of clinical pregnancies and successful live births (Baruch et al., 2008) . As a result, the longterm health-related outcomes of children born after the use of PGD remains unknown.
Fortuny et al. examined opinions about assisted reproduction among 77 individuals undergoing genetic testing (Fortuny et al., 2009) . Participants held favourable attitudes towards PGD and this was not associated with already having a child. Prior to receiving test results, 36% of participants would decide to have children whether the results were positive or negative and 30% indicated they would consider adoption if indeed they were a BRCA carrier. At least half of the respondents indicated they would consider PGD if their results were positive. Although there were only a few men in the study (n ¼ 10), the researchers conclude that reproductive decision-making among high-risk individuals may be impacted by genetic testing results.
Limitations
There are limitations to our findings. Respondents were asked whether they and their spouse (significant other) would 'ever consider the use of PGD'. There is a possibility of variance in relevance of the question due to marital status, as some survey respondents were single. Additionally, as with other anonymous web-based surveys, we cannot verify clinical characteristics (e.g. participation in genetic testing, BRCA status personal/family cancer history) that may impact consideration of PGD use. Self-selection bias may have also been a factor with respondents who completed the survey as they may have had an existing interest in ART compared with those who did not participate. 30% of men in this study selected they would 'prefer not to answer' when asked to confirm the BRCA positive status of their spouse, partner or first degree relative. Thus, this artefact then disallowed the possibility of comparing responses between men who disclosed a personal genetic mutation versus those who had a spouse or partner who was positive. Such comparisons may have yielded important information about considerations of PGD by men. Lastly, spouses or partners of the male participants were not surveyed. Therefore, we cannot compare and/or analyse attitudes about PGD from a couples' perspective which may be more influential in ultimate uptake of PGD. However, the data from the respondents does give insight into men's perceptions of PGD.
Conclusions
High-risk men represent a unique community thatmay require assistance with reproductive decision-making. public, high-risk men have limited knowledge about PGD, but do perceive benefits associated with this technology. PGD is a technique which could lessen parental worries about passing on a genetic mutation to future offspring. Further studies are needed to determine how high risk-males access health information. Whether information is received via the Internet, physicians and/or spouses (partners), educational programmes designed for high-risk men could lessen concerns among couples who are contemplating alternative assisted reproduction. Men may play a pivotal role in decisions about the use of assisted reproduction, which has been traditionally considered only among female populations or couples. The attitudes of the female partners' of male BRCA carriers may influence whether or not as a couple, PGD is pursued. Future studies should examine the emotional burdens of reproductive decision-making when deciding whether or not to pursue PGD. The distress and guilt of the parent with the known hereditary risk is of particular concern. The impact of societal and governmental debates surrounding the use of PGD for adult onset hereditary cancers should also be explored within these high-risk populations, particularly in countries where such applications of PGD is not allowed or currently available. Future studies could be conducted via additional anonymous surveys or personal interviews. In addition, adult children of male BRCA carriers are another population that warrants examination about knowledge and attitudes as well as emotional burden and distress. Data from each of these group types could lead to the design of tailored and effective interventions to improve knowledge, reduce distress and aid in decision-making.
Clinical geneticists, genetic counsellors and other health care professionals should consider how BRCA genetic testing impacts reproductive decision-making. It is important for genetic counsellors to be sensitive to the needs of high-risk men and incorporate topics related to reproductive decision-making into the genetic counselling session, allowing men to make informed decisions. Further research is needed with a larger sample of high-risk men to identify specific informational needs and the health care professional who is best suited to provide this information.
